Syndax Announces Participation in March Investor Conferences

Rhea-AI Summary

Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company focused on developing cancer therapies, has announced its participation in two major investor conferences in March 2025. The company's CEO Michael A. Metzger and management team members will attend the TD Cowen 45th Annual Health Care Conference in Boston on March 4, featuring a fireside chat at 3:10 p.m. ET, and the Barclays 27th Annual Global Healthcare Conference in Miami Beach on March 13, with a fireside chat scheduled for 8:30 a.m. ET.

Live webcasts of both presentations will be available on Syndax's website in the Investor section at www.syndax.com, where replays will also be accessible for a time.

WALTHAM, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, as well as members of the Syndax management team, will participate in the following upcoming investor conferences:

• TD Cowen 45th Annual Health Care Conference in Boston, MA, with a fireside chat on Tuesday, March 4, 2025, at 3:10 p.m. ET
• Barclays 27th Annual Global Healthcare Conference in Miami Beach, FL, with a fireside chat on Thursday, March 13, 2025, at 8:30 a.m. ET

A live webcast of the fireside chats will be available in the Investor section of the Company's website at www.syndax.com, where a replay will also be available for a limited time.

About Syndax

Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include Revuforj^® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com/ or follow the Company on X and LinkedIn.

Syndax Contacts

Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827

SNDX-G

FAQ

When is Syndax Pharmaceuticals (SNDX) presenting at the TD Cowen Health Care Conference?

Syndax Pharmaceuticals (SNDX) will present at the TD Cowen 45th Annual Health Care Conference in Boston on Tuesday, March 4, 2025, at 3:10 p.m. ET with a fireside chat.

Who will represent SNDX at the March 2025 investor conferences?

Michael A. Metzger, Chief Executive Officer of Syndax, along with other members of the Syndax management team, will represent SNDX at the March 2025 investor conferences.

What investor conferences will Syndax Pharmaceuticals (SNDX) attend in March 2025?

Syndax Pharmaceuticals (SNDX) will attend the TD Cowen 45th Annual Health Care Conference in Boston on March 4 and the Barclays 27th Annual Global Healthcare Conference in Miami Beach on March 13, 2025.

How can investors access Syndax's (SNDX) presentations at the March 2025 conferences?

Investors can access live webcasts of Syndax's presentations in the Investor section of the company's website at www.syndax.com, where replays will also be available for a time.